In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Oruka Therapeutics, with a price target of $44.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison’s rating is based on several compelling factors. The clearance of ORKA-001’s IND for its Phase 2a trial in moderate-to-severe psoriasis marks a significant milestone, with expectations for initial efficacy and response duration data by the second half of 2026. The trial’s design, which includes a randomized, double-blind, placebo-controlled setup, aims to evaluate the safety and efficacy of ORKA-001, potentially offering greater efficacy than current market options like Skyrizi. This could position ORKA-001 as a differentiated treatment with extended off-treatment remissions.
Moreover, the anticipated interim pharmacokinetic data for ORKA-001, expected to demonstrate a class-leading half-life, suggests the potential for improved efficacy and reduced injection frequency. This could result in a lower annual injection burden, which is appealing to patients, payors, and prescribers. Additionally, the drug’s subcutaneous formulation aligns with existing therapies, and its potential for Q6M to Q12M dosing could enhance patient compliance and satisfaction. These factors collectively contribute to the positive outlook for Oruka Therapeutics, justifying the Buy rating.
Harrison covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Theravance Biopharma, and Oruka Therapeutics. According to TipRanks, Harrison has an average return of 6.5% and a 47.16% success rate on recommended stocks.
In another report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $47.00 price target.